Strategies to Manage Antibody Drug Conjugates (ADC) - Related Toxicities in Breast Cancer - Episode 7

Overview of Cardiotoxicity Risk with T-DXd and Monitoring Strategies along with Anti-Nausea strategies

,

Experts on breast cancer discuss the potential adverse events related to trastuzumab deruxtecan (T-DXd).

EP. 1: Overview of Current ADCs in Breast Cancer
EP. 2: ADCs in Breast Cancer: Mechanism of Action, and Components
EP. 3: Overview of SG-Related Neutropenia Rates in Real-Life Setting and in Clinical Trials
EP. 4: Expert Perspectives on the Management of SG-Related Neutropenia
EP. 5: Navigating SG-related Diarrhea
EP. 6: Expert Insights: SG Adverse Events Management including Alopecia & Nausea
Now Viewing
EP. 7: Overview of Cardiotoxicity Risk with T-DXd and Monitoring Strategies along with Anti-Nausea strategies
EP. 8: Clinical Management Considerations: Pneumonitis associated with T-DXd
EP. 9: Expert Perspectives: T-DM1 Adverse Events Overview and Management Strategies
EP. 10: Role of Multidisciplinary Team in the Management of Patients Receiving ADCs in Breast Cancer
EP. 11: Future Perspectives on ADCs in Breast Cancer
EP. 12: Expert Insights: Investigational ADCs Safety Profiles
EP. 13: Key Takeaways and Clinical Practice Pearls in the Treatment of Patients with Breast Cancer Receiving ADCs

Video content above is prompted by the following:

  • Can you describe the cardiotoxicity risk with T-DXd and the mechanism behind cardiovascular toxicity?
  • Please comment on your monitoring strategy for cardiotoxicity with T-DXd.
  • What patient symptoms do you monitor for? What are your left ventricular ejection fraction cutoffs to initiate, hold/delay, and discontinue therapy?